A Study of Esketamine Nasal Spray in Korean Participants With Treatment-resistant Depression
NCT07053345
·
clinicaltrials.gov ↗
PHASE4
Phase
RECRUITING
Status
47
Enrollment
INDUSTRY
Sponsor class
Conditions
Depressive Disorder, Treatment-Resistant
Interventions
DRUG:
Esketamine 56 mg
DRUG:
Esketamine 84 mg
Sponsor
Janssen Korea, Ltd., Korea